C44Mab-1-mG2a

C44Mab-1-mG2a is an **experimental monoclonal antibody** targeting CD44 variant 9 (CD44v9), a splice variant of the CD44 cell surface glycoprotein, which is frequently overexpressed in multiple cancers and associated with cancer stemness, recurrence, and resistance. C44Mab-1 itself was originally developed as an IgG1, kappa isotype using the Cell-Based Immunization and Screening (CBIS) method, and C44Mab-1-mG2a is a mouse IgG2a version engineered for enhanced effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)[3]. The antibody specifically recognizes CD44v9-expressing tumor cells and has been studied in preclinical models for antitumor activity, including flow cytometry, immunohistochemistry, and xenograft experiments[3][1]. The mG2a engineering is intended to optimize the therapeutic potential in murine cancer models by engaging murine immune effector pathways.